Amneal Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Amneal Pharmaceuticals (AMRX) Misses Q1 EPS by 4c, Revenues Beat; Affirms FY19 EPS Outlook
May 9, 2019 6:37 AM EDTAmneal Pharmaceuticals (NYSE: AMRX) reported Q1 EPS of $0.14, $0.04 worse than the analyst estimate of $0.18. Revenue for the quarter came in at $446.12 million versus the consensus estimate of $438.76 million.
"Amneal is off to a good start in 2019 as we continue to optimize our business and diversify our portfolio," said Rob Stewart, President and CEO of Amneal. "We increased generics first quarter combined net... More
